Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sabine Schroeder has a total of 132 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    X-linked adrenoleukodystrophy in Sri Lanka: Case series

    by D M Vidanapathirana, P M S Fernando, S Madanayake, K L S P K M Jayasena, N Atapattu, S Schröder, A B Moser, E Jasinge

  • Open Access

    Transcobalamin II deficiency with low vitamin B12 levels associated with a novel variant in the TCN2 gene

    by Kaushalya Pussagoda, Imalke Kankananarachchi, Waruna Heshantha, Charith Prabhawitha, Anura Jayawadana, Eresha Jasinge, Chandima Thewarapperuma, Sabine Schröder, Nayana Liyanarachchi

  • Open Access

    Glucosylsphingosine (Lyso-Gb1) Dynamics in Untreated States in Gaucher Disease

    by Tama Dinur, Peter Bauer, Sabine Schroeder, Guido Kramp, Christian Beetz, Michal Becker-Cohen, Majdolen Istaiti, Dafna Frydman, Elena Shulman, Ari Zimran, et al.

    Glucosylsphingosine (lyso-Gb1) serves as a biomarker for evaluating disease activity in Gaucher disease (GD). While treatment-related changes are documented, the dynamics of lyso-Gb1 during untreated states remain poorly understood. This retrospective, longitudinal cohort study utilized a large GD database comprising 701 patients and over 6200 visits with lyso-Gb1 measurements. Patients with at least two untreated visits were included in the analysis (n = 272). A significant change was defined as ≥50 ng/mL for lyso-Gb1, ≥1 g/dL for hemoglobin, and ≥50 × 109/L for platelet count. Multivariable logistic regression analyses identified clinical factors associated with lyso-Gb1 decline or an increase. During untreated states, 35 patients (12.9%; 95% CI 9.4–17.5%) exhibited a decline in lyso-Gb1, with a median decrease of 96.3 ng/mL. This decline was more common in females (OR 3.50, p = 0.032) and associated with higher initial lyso-Gb1 levels (p < 0.001) and baseline hemoglobin (p = 0.032). An increase in lyso-Gb1 was observed in 98 patients (36.0%; 95% CI 30.5–41.9%), with a median rise of 135.1 ng/mL. This increase correlated with lower baseline platelet counts (p = 0.003), lower baseline hemoglobin (p = 0.002), and longer follow-up duration (p = 0.001). In many cases, lyso-Gb1 increases were observed without a preceding change in hemoglobin or platelet count. In summary, declines in lyso-Gb1 in untreated states are rare but possible. The association with female sex may reflect inflammatory effects. Although increases in lyso-Gb1 were expected without treatment, they occurred mainly in patients with higher disease severity markers. Nevertheless, most patients in the untreated states remained stable within ±50 ng/mL. These findings demonstrate a heterogeneous trajectory of lyso-Gb1 across untreated states and highlight the importance of interpreting lyso-Gb1 changes within the clinical context when making treatment decisions.

  • Open Access

    A Retrospective Cohort Study of the GLA c.937G > T, p.Asp313Tyr Variant With No Evidence of an Association With Fabry Disease

    by Tobias Boettcher, Christian Beetz, Daniel Schulze, Deepa Saravanakumar, Emir Zonic, Sabine Schroeder, Anett Kaune, Sebastian Oppermann, Omid Paknia, Jorge Pinto Basto, et al.

    Fabry disease (FD) is a multisystemic disorder caused by pathogenic variants in the α-galactosidase (GLA) gene. There is ongoing debate on the disease-causing properties of the GLA variant NM_000169.3: c.937G > T, p.Asp313Tyr (D313Y). Like many others, we recently reclassified this variant from “variant of uncertain significance” to “benign.” By leveraging Centogene's Biodatabank, we reassessed our classification and analyzed all samples (n = 38,242) molecularly tested for FD from Germany between 2015 and 2020 for GLA genotypes, clinical presentations, and biochemical phenotypes. The allele frequency of GLA variant p.Asp313Tyr in our cohort was increased compared with gnomAD v4.1.0 data for European (non-Finnish) population resulting in an odds ratio of 2.13 (95% CI 1.94–2.33; p < 0.0001). Compared with individuals without any GLA variant, there was no specific clinical nor biochemical phenotype in this group, supporting a diagnosis of FD. GLA variant p.Asp313Tyr is to be classified as a benign variant and does not cause FD. Because an enrichment of patients with this variant in specific high-risk populations has been seen in this cohort and by other groups, properly designed case-control studies are needed to clarify a potential role of p.Asp313Tyr as risk factor or modifier of a FD-independent dysfunction.


  • Open Access

    Genotypic Spectrum in a Cohort of Sri Lankan Patients With Homocystinuria

    by Hewa Warawitage Dilanthi, Kandana Liyanage Subhashinie Jayasena, Nambage Dona Priyani Dhammika, Neluwa Liyanage Ruwan Indika, Matara Mahavidanage Nishani De Silva, Imalke Kankananarachchi, Pushpa Malkanthi Gardiye Punchihewa, Dharma Irugalbandara, Sabine Schroeder, Kosala Karunaratne, et al.

    Homocystinuria due to cystathionine beta‐synthase (CBS) deficiency is a rare metabolic disorder inherited as an autosomal recessive trait. Spectrum of genetic variants in CBS gene and their correlation with the phenotypes of homocystinuria in Sri Lankan patients have not been reported to date. The objective of this study was to identify the genotypes and genotype–phenotype correlations in a cohort of Sri Lankan patients with homocystinuria due to CBS deficiency. We determined the variants in CBS gene in 14 Sri Lankan patients with homocystinuria, from 9 unrelated families. The clinical features and the biochemical response to pyridoxine were studied for further correlations. Among the 14 patients, the common clinical features were ectopia lentis (100%), intellectual disability (92%) and marfanoid features (78%) at presentation while three of them had developed osteoporosis (21%). Median age at diagnosis was 8 years (range 2–12). Three pathogenic variants (c.1006C>T, c.785C>T and c.19del) and two likely pathogenic variants (c.869C>T, c.772G>A) in CBS gene were identified. Thirteen patients with homozygous genotypes were non‐responsive to pyridoxine while the only patient with the compound heterozygous genotype (c.869C>T/c.772G>A) responded to pyridoxine treatment. The genotypic spectrum observed in Sri Lankan patients is unique and mostly associated with pyridoxine non‐responsiveness. The majority of the patients were identified clinically at a later stage of the disease due to lack of a screening programme in the country. Therefore, it is important to improve the awareness of the disease among the clinicians in the interest of early diagnosis and early commencement of metabolic treatment.


  • Open Access

    Hereditary Transthyretin-Related Amyloidosis Ongoing Observational Study: A Baseline Report of the First 3167 Participants

    by Sabine Rösner, Luba M. Pardo, Aida M. Bertoli-Avella, Volha Skrahina, Pierre Engel, Sabine Schröder, Susan Zielske, Valerie Bonke, Janett Kreth, Gina Westphal, et al.

    Background: Hereditary transthyretin-related amyloidosis is a clinically heterogeneous autosomal dominant disease caused by pathogenic variants in the TTR gene (hATTR amyloidosis). Objective: The current study describes the demographic, clinical, and genetic characteristics of patients with suspected hATTR amyloidosis. Methods: This study is part of the “Hereditary transthyretin-related amyloidosis and longitudinal monitoring of TTR-positive patients” (TRAMmoniTTR) study. This study included 3167 participants, along with their clinical details. Principal component (PC) analysis was used to analyze their clinical symptomatology. Next-generation sequencing of the TTR gene was performed and genotype–phenotype relationships were investigated. We compared the demographic and clinical characteristics using the principal components (PCs) and also compared participants with and without the TTR pathogenic variants. Results: We identified five main clinical phenotypes out of 22 single symptoms that explained 49% of the variation. The first two PCs referred to polyneuropathy and cardiomyopathy. We found significant differences between gender and PC-polyneuropathy and PC-cardiomyopathy, with male over-representation in the higher quantiles of PC-polyneuropathy and male under-representation in the lowest quantiles of PC-cardiomyopathy. We identified 92 participants with hATTR (3%), exhibiting 17 unique heterozygous TTR variants. The p.Val50Met variant was the most frequent. Furthermore, 503 participants (20%) were identified with ATTR and no relevant TTR variants (ATTRwt). We detected significant differences between the ATTRwt and hATTR groups, with male gender predominance in only the ATTRwt group and a positive family history of polyneuropathy and/or cardiomyopathy among the hATTR participants. Conclusions: The current clinical and genetic characterization of this cohort serves as a foundation for further longitudinal monitoring and assessment.


  • Open Access

    L2-hydroxyglutaric aciduria presenting with learning disability and cerebellar signs: A case report

    by Maththage H. K. Amarasekara, Arndt Rolfs, Christian Beetz, Sabine Schroder, Ranawaka Arachchige S. R. Gunasekara, Pyara Rathnayake, Eresha Jasinge

    L-2-hydroxyglutaric aciduria (L2HGA) is a rare, autosomal recessive neurometabolic disorder due to variants in the L2HGDH gene, which encodes L-2-hydroxyglutarate dehydrogenase (L2HGDH), an enzyme involved in tricarboxylic acid cycle. Deficiency of L2HGDH causes leukoencephalopathy predominantly affecting the cerebellum. This case presents L2HGA in a 12-year-old Sri Lankan boy born to third-degree consanguineous parents, who also showed learning disability and bilateral cerebellar signs. Magnetic resonance imaging (MRI) of the brain revealed T2/FLAIR hyperintensities in bilateral symmetrical subcortical white matter involving the cerebellum. A diagnosis of 2-hydroxyglutaric aciduria was made after a massive peak of 2-hydroxyglutaric acid (2HG) was observed in the analysis of urine organic acids (UOA) using gas chromatography/mass spectrometry. Genetic variant analysis revealed two heterozygous pathogenic variants in the L2HGDH gene, confirming the genetic diagnosis of autosomal recessive L2HGA. Parental genetic testing confirmed the trans phase of the variants in the index patient and their carrier status of a pathogenic L2HGDH variant. Despite typical clinical features and classical MRI findings, initial clues toward the diagnosis are mainly derived from the UOA analysis. In conclusion, this case underscores the paramount importance of analyzing the UOA profile in the process of identifying rare metabolic causes, such as L2HGA, that contribute to learning disability with neurological involvement in children.

  • Open Access

    Perfiles clínicos, bioquímicos y moleculares de tres neonatos de Sri Lanka con déficit de piruvato carboxilasa

    by Eresha Jasinge, Mihika Fernando, Neluwa-Liyanage Ruwan Indika, Pyara Dilani Ratnayake, Nalin Gamaathige, Ratnanathan Ratnaranjith, Sabine Schroeder, Patricia Jones, Skrahina Volha, Subhashinie Jayasena, et al.

    Resumen: Objetivos: La piruvato carboxilasa (PC), una enzima mitocondrial, cataliza la conversión de piruvato, producto final de la glucólisis, en oxaloacetato, un intermediario del ciclo del ácido tricarboxílico. El déficit de piruvato carboxilasa, un trastorno raro, se manifiesta en tres fenotipos clínicos y bioquímicos: tipo de inicio neonatal (tipo A), tipo de inicio infantil (tipo B) y un tipo benigno (tipo C). Caso clínico: Presentamos el caso de tres neonatos de Sri Lanka, incluidos dos hermanos, de dos familias no emparentadas, con déficit de piruvato carboxilasa (DPC). Los tres desarrollaron dificultad respiratoria en las primeras horas de vida. Los dos hermanos presentaron las alteraciones bioquímicas típicas del tipo B. El tercer neonato presentaba niveles normales de citrulina y lisina, niveles moderados de lactato, lesiones quísticas paraventriculares, deformidades óseas y una nueva variante homocigótica sin sentido c.2746G>C [p.(Asp916His)] en el gen PC, indicativos bioquímicos de DPC tipo A. Conclusiones: Nuestros hallazgos indican la urgencia de realizar estudios analíticos en los neonatos que presenten taquipnea con acidosis metabólica concomitante, dado que la identificación temprana es crucial para el manejo del paciente y la prestación de consejo genético a la familia. Son necesarios más estudios para identificar los síntomas y alteraciones bioquímicas concurrentes en los diferentes fenotipos de déficit de piruvato carboxilasa.


  • Open Access

    P219: Genetic, biochemical and clinical properties of GLA p.Asp313Tyr variant in a large German cohort

    by Tobias Boettcher, Christian Beetz, Daniel Schulze, Deepa Saravanakumar, Emir Zonic, Sabine Schroeder, Anett Kaune, Omid Paknia, Jorge Pinto Basto, Peter Bauer